Literature DB >> 31870649

Imidazolidine-2,4,5- and pirimidine-2,4,6-triones - New primary pharmacophore for soluble epoxide hydrolase inhibitors with enhanced water solubility.

Vladimir Burmistrov1, Christophe Morisseau2, Vladimir D'yachenko3, Dmitry Karlov4, Gennady M Butov3, Bruce D Hammock5.   

Abstract

A series of inhibitors of the soluble epoxide hydrolase (sEH) containing imidazolidine-2,4,5-trione or pirimidine-2,4,6-trione has been synthesized. Inhibition potency of the described compounds ranges from 8.4 μM to 0.4 nM. The tested compounds possess higher water solubility than their preceding ureas. Molecular docking indicates new bond between the triones and the active site of sEH that in part explain the observed potency of the new pharmacophores. While less potent than the corresponding ureas, the modifications of urea group reported herein yield compounds with higher water solubility, thus permitting easier formulation.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adamantane; Epoxyeicosatrienoic acids; Imidazolidine-2,4,5-trione; Inhibitor; Pirimidine-2,4,6-trione; Soluble epoxide hydrolase; Urea

Year:  2019        PMID: 31870649      PMCID: PMC6957307          DOI: 10.1016/j.bmcl.2019.126908

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  15 in total

1.  Symmetric adamantyl-diureas as soluble epoxide hydrolase inhibitors.

Authors:  Vladimir Burmistrov; Christophe Morisseau; Kin Sing Stephen Lee; Diyala S Shihadih; Todd R Harris; Gennady M Butov; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2014-03-20       Impact factor: 2.823

2.  An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.

Authors:  John D Imig; Xueying Zhao; Constantine Z Zaharis; Jeffrey J Olearczyk; David M Pollock; John W Newman; In-Hae Kim; Takaho Watanabe; Bruce D Hammock
Journal:  Hypertension       Date:  2005-09-12       Impact factor: 10.190

3.  Effects of adamantane alterations on soluble epoxide hydrolase inhibition potency, physical properties and metabolic stability.

Authors:  Vladimir Burmistrov; Christophe Morisseau; Todd R Harris; Gennady Butov; Bruce D Hammock
Journal:  Bioorg Chem       Date:  2017-12-30       Impact factor: 5.275

4.  Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys.

Authors:  A Ulu; Se Appt; C Morisseau; S H Hwang; P D Jones; T E Rose; H Dong; J Lango; J Yang; H J Tsai; C Miyabe; C Fortenbach; M R Adams; B D Hammock
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 5.  Humble beginnings with big goals: Small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders.

Authors:  Sydney Zarriello; Julian P Tuazon; Sydney Corey; Samantha Schimmel; Mira Rajani; Anna Gorsky; Diego Incontri; Bruce D Hammock; Cesar V Borlongan
Journal:  Prog Neurobiol       Date:  2018-11-14       Impact factor: 11.685

6.  Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.

Authors:  Sean D Kodani; Saavan Bhakta; Sung Hee Hwang; Svetlana Pakhomova; Marcia E Newcomer; Christophe Morisseau; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2018-01-04       Impact factor: 2.823

7.  Sequence similarity of mammalian epoxide hydrolases to the bacterial haloalkane dehalogenase and other related proteins. Implication for the potential catalytic mechanism of enzymatic epoxide hydrolysis.

Authors:  M Arand; D F Grant; J K Beetham; T Friedberg; F Oesch; B D Hammock
Journal:  FEBS Lett       Date:  1994-02-07       Impact factor: 4.124

8.  Epoxyeicosatrienoic acids regulate Trp channel dependent Ca2+ signaling and hyperpolarization in endothelial cells.

Authors:  Ingrid Fleming; Alexandra Rueben; Rüdiger Popp; Beate Fisslthaler; Susanne Schrodt; Anna Sander; Judith Haendeler; John R Falck; Christophe Morisseau; Bruce D Hammock; Rudi Busse
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-09-13       Impact factor: 8.311

9.  Orally bioavailable potent soluble epoxide hydrolase inhibitors.

Authors:  Sung Hee Hwang; Hsing-Ju Tsai; Jun-Yan Liu; Christophe Morisseau; Bruce D Hammock
Journal:  J Med Chem       Date:  2007-07-06       Impact factor: 7.446

10.  Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.

Authors:  Sung Hee Hwang; Aaron T Wecksler; Guodong Zhang; Christophe Morisseau; Long V Nguyen; Samuel H Fu; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2013-05-15       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.